Expand BMY Menu
BMY MENU

BMY Latest Press Releases

-- April 12, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY PRNewswire 2:45 PM

-- April 8, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY Globe Newswire 4:45 PM
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) Business Wire 11:30 AM

-- April 6, 2024 --

Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society Business Wire 1:15 PM
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society Business Wire 1:15 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY PRNewswire 1:04 AM

-- April 5, 2024 --

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy Business Wire 9:05 AM

-- April 4, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY PRNewswire 7:20 PM

-- April 2, 2024 --

European Commission Expands Approval of Bristol Myers Squibb's Reblozyl (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Business Wire 8:08 PM
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals Business Wire 6:59 AM

-- April 1, 2024 --

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic... Business Wire 7:30 AM

-- March 31, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY Globe Newswire 11:07 AM

-- March 28, 2024 --

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Business Wire 4:05 PM
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease Business Wire 4:01 PM
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results Globe Newswire 7:30 AM

-- March 27, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY PRNewswire 7:53 PM

-- March 26, 2024 --

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes Business Wire 6:59 AM

-- March 25, 2024 --

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio Business Wire 8:00 AM

-- March 23, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY Globe Newswire 4:45 PM

-- March 21, 2024 --

Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth InvestorBrandMedia 7:20 PM

-- March 20, 2024 --

Bristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Business Wire 4:45 PM
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma Business Wire 6:59 AM

-- March 19, 2024 --

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY PRNewswire 5:35 PM
Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in "SO, Have You Found It?" Campaign Business Wire 6:59 AM

-- March 18, 2024 --

Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion Business Wire 9:52 AM
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio Business Wire 8:44 AM
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma Globe Newswire 8:00 AM

-- March 15, 2024 --

FDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy Business Wire 6:27 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY Globe Newswire 12:12 PM

-- March 14, 2024 --

U.S. FDA Approves Bristol Myers Squibb's Breyanzi as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Business Wire 9:35 PM

-- March 11, 2024 --

Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024 Business Wire 4:16 PM

-- March 7, 2024 --

U.S. Food and Drug Administration Approves Opdivo (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma Business Wire 2:23 PM

-- March 6, 2024 --

Bristol Myers Squibb to Participate in Upcoming Investor Conferences Business Wire 4:17 PM

-- March 1, 2024 --

Bristol Myers Squibb Announces Dividend Business Wire 4:16 PM

-- February 29, 2024 --

Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis Business Wire 6:59 AM
Tapestry, Inc. Appoints Kevin Hourican and David Elkins to Board of Directors Business Wire 6:45 AM

-- February 28, 2024 --

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update Globe Newswire 7:34 AM

-- February 26, 2024 --

Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference Business Wire 4:16 PM
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform Business Wire 8:35 AM

-- February 23, 2024 --

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer Business Wire 6:59 AM
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS) Business Wire 6:59 AM

-- February 22, 2024 --

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial Globe Newswire 7:00 AM

-- February 20, 2024 --

Arkhouse Nominates Nine Highly Qualified, Independent Candidates for Election to Macy's Board of Directors Business Wire 1:10 PM
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or... Business Wire 6:59 AM

-- February 14, 2024 --

Bristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes Business Wire 7:57 PM
Bristol Myers Squibb Recommends Stockholders Reject "Mini-Tender" Offer by Tutanota LLC Business Wire 4:16 PM
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX Business Wire 4:10 PM
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies Globe Newswire 8:30 AM
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors Business Wire 6:59 AM

-- February 13, 2024 --

VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence Business Wire 8:00 AM

-- February 12, 2024 --

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq CBAY), Masonite International Corporation (NYSE DOOR), ZeroFox Holdings, Inc. (Nasdaq ZFOX), RayzeBio, Inc. (Nasdaq RYZB) Globe Newswire 11:17 AM
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period Business Wire 6:59 AM

-- February 8, 2024 --

Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results Business Wire 4:15 PM

-- February 7, 2024 --

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer Business Wire 6:59 AM

-- February 5, 2024 --

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE CTLT), Everbridge, Inc. (Nasdaq EVBG), Slam Corp. (Nasdaq SLAM), Karuna Therapeutics, Inc. (Nasdaq KRTX) Globe Newswire 12:59 PM
Bristol Myers Squibb Named One of America's Most JUST Companies by JUST Capital and CNBC Business Wire 9:00 AM
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study Business Wire 6:59 AM

-- February 2, 2024 --

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023 Business Wire 6:59 AM

-- January 30, 2024 --

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq AVRO), California BanCorp (Nasdaq CALB), Exro Technologies Inc. (OTC EXROF), Karuna Therapeutics, Inc. (Nasdaq KRTX) Globe Newswire 11:13 AM
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030 Globe Newswire 9:15 AM
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL) Business Wire 6:59 AM

-- January 27, 2024 --

Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial Business Wire 10:00 AM

-- January 26, 2024 --

RAYZEBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB PRNewswire 10:03 PM
KARUNA THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX PRNewswire 8:34 PM
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST) Globe Newswire 4:49 PM
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma Business Wire 7:13 AM

-- January 23, 2024 --

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio Business Wire 8:30 AM

-- January 22, 2024 --

Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire 5:05 PM
Opdivo (nivolumab) in Combination with CABOMETYX (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma Business Wire 5:00 PM
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST) Globe Newswire 10:20 AM

-- January 20, 2024 --

Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial Business Wire 10:00 AM

-- January 17, 2024 --

Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers Business Wire 6:59 AM

-- January 10, 2024 --

Breakthrough Properties Acquires Majority Interest in Callan Ridge, A Newly-Constructed, Fully-Leased Life Science Campus in Torrey Pines PRNewswire 4:15 PM
Healthpeak Properties Enters into a New $236 Million Joint Venture with Breakthrough Properties on the Callan Ridge Lab Campus in Torrey Pines Business Wire 4:15 PM

-- January 4, 2024 --

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq RYZB), Gracell Biotechnologies Inc. (Nasdaq GRCL), Daseke, Inc. (Nasdaq DSKE), Karuna Therapeutics, Inc. (Nasdaq KRTX) Globe Newswire 11:05 AM

-- January 2, 2024 --

European Medicines Agency Validates Bristol Myers Squibb's Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors Business Wire 6:59 AM

-- December 31, 2023 --

RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB Business Wire 5:56 PM
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX Business Wire 5:49 PM

-- December 26, 2023 --

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq RYZB), Gracell Biotechnologies Inc. (Nasdaq GRCL), Daseke, Inc. (Nasdaq DSKE), Karuna Therapeutics, Inc. (Nasdaq KRTX) Globe Newswire 2:43 PM
RYZB News: Johnson Fistel Investigates Proposed Sale of RayzeBio; Is $62.50 a Fair Price? Globe Newswire 9:23 AM
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio Globe Newswire 7:13 AM
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio Business Wire 6:59 AM

-- December 22, 2023 --

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc. PRNewswire 3:30 PM
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion Business Wire 9:13 AM
Bristol Myers Squibb to Present at J.P. Morgan's 42nd Annual Healthcare Conference Business Wire 6:59 AM
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics Business Wire 6:59 AM

-- December 20, 2023 --

Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference Business Wire 4:16 PM

-- December 15, 2023 --

Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer Business Wire 4:54 PM
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024 Business Wire 6:59 AM

-- December 14, 2023 --

Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb PRNewswire 7:00 AM

-- December 11, 2023 --

Two Early Studies Evaluating Potential First-in-Class CELMoD Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023 Business Wire 9:00 PM
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs Business Wire 8:30 PM
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3 Business Wire 7:30 PM
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1 Business Wire 4:15 PM

-- December 10, 2023 --

Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia Business Wire 9:26 PM

-- December 9, 2023 --

Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Nave Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023 Business Wire 5:00 PM

-- December 7, 2023 --

Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite InstabilityHigh or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary... Business Wire 6:59 AM
Bristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization Business Wire 6:30 AM

-- December 6, 2023 --

Bristol Myers Squibb Announces Dividend Increase Business Wire 4:16 PM

-- December 5, 2023 --

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic... Business Wire 6:59 AM

-- November 28, 2023 --

Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology PRNewswire 6:30 AM

-- November 20, 2023 --

Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma Business Wire 6:59 AM